SLS Stock In Spotlight: First AML Patient Enrolled In Phase 2 Leukemia Trial
Synopsis
The study aims to evaluate SLS009’s effectiveness in a molecularly defined cohort of frontline leukemia patients, enrolling approximately 80 patients across two high-priority groups.
SELLAS Life Sciences Group, Inc. (SLS) on Thursday said it has enrolled its first patient in a Phase 2 trial of SLS009 (tambiciclib), a selective CDK9 inhibitor for patients with acute myeloid leukemia (AML).
The trial aims to assess efficacy in first-line AML treatment and will enroll approximately 80 patients across two high-need cohorts.
“By targeting molecularly defined subgroups and those demonstrating early non-response, we aim to address a critical need in frontline AML and position SLS009 for potential registrational development.”
-Angelos Stergiou, President and CEO, SELLAS
Following the update, SELLAS Life Sciences stock traded over 1% higher in Thursday’s premarket.
Get updates to this developing story directly on Stocktwits.<
Stay updated with all the latest Business News, including market trends, Share Market News, stock updates, taxation, IPOs, banking, finance, real estate, savings, and investments. Track daily Gold Price changes, updates on DA Hike, and the latest developments on the 8th Pay Commission. Get in-depth analysis, expert opinions, and real-time updates to make informed financial decisions. Download the Asianet News Official App from the Android Play Store and iPhone App Store to stay ahead in business.